Estudou-se a possível toxicidade do uso prolongado do amitraz em eqüinos utilizando-se seis éguas Puro Sangue Inglês, as quais receberam injeções intravenosas de amitraz (0,05, 0,10 ou 0,15 mg/kg) semanalmente, durante quatro meses (grupo experimental). Outros oito animais (grupo-controle), seguindo o mesmo esquema de administração e período, receberam o veículo dimetilformamida. Ao final desse período colheram-se amostras de sangue dos animais e compararam-se as médias dos valores obtidos para as seguintes variáveis do sangue: hemograma completo, fosfatase alcalina, gama-glutamiltransferase, nitrogênio uréico, desidrogenase láctica, aspartato aminotransferase, creatina fosfoquinase, glucose, albumina, proteína total, creatinina, Na+ , K+, Cl- e CO2. Apenas as médias dos valores de nitrogênio uréico dos animais submetidos ao tratamento com amitraz foram diferentes das médias dos valores obtidos para o grupo-controle. As análises das características hematimétricas mostraram que não houve diferenças significativas quando se compararam os dois grupos. As dosagens de eletrólitos no sangue também demonstraram que o tratamento prolongado com amitraz não causou alterações significativas nas características analisadas. O amitraz na dosagem empregada não induziu efeitos tóxicos sobre órgãos vitais, mesmo após administração prolongada.

With the aim of determining the possible toxicity of amitraz after its prolonged use in horses, six English Thoroughbred horses received intravenous injections of amitraz (0.05, 0.10 or 0.15 mg/kg) weekly for four months, constituting the experimental group. Eight other animals (control group), via the same route following the same drug administration schedule and period of time, received the vehicle, dimethylformamide. At the end of this period, blood was collected from all the animals, and a comparison was made of the means of the values obtained for the various blood analyses: complete hemogram, alkaline phosphatase, gamma-glutamyltransferase, blood urea nitrogen, lactate dehydrogenase, aspartate aminotransferase, creatine phosphokinase, glucose, albumin, total protein, creatinine, Na+ , K+, Cl- and CO2. The results for the biochemical characteristics showed that only the mean value for urea of the animals submitted to treatment with amitraz was significantly different than the mean value obtained for the control group. The analyses of the hematological characteristics showed that no significant differences between groups were observed. Similarly, the measurement of blood electrolyte levels demonstrated that long-term treatment with amitraz did not cause significant changes in the variables analyzed. The results indicate that amitraz, given in the doses employed in this study, did not show signs of inducing toxic effects in vital organs, even after prolonged administration.

In the present study we evaluated the precision of the ELISA method to quantify caffeine in human plasma and compared the results with those obtained by gas chromatography. A total of 58 samples were analyzed by gas chromatography using a nitrogen-phosphorus detector and routine techniques. For the ELISA test, the samples were diluted to obtain a concentration corresponding to 50% of the absorbance of the standard curve. To determine whether the proximity between the I50 of the standard curve and that of the sample would bring about a more precise result, the samples were divided into three blocks according to the criterion of difference, in modulus, of the I50 of the standard curve and of the I50 of the sample. The samples were classified into three groups. The first was composed of 20 samples with I50 up to 1.5 ng/ml, the second consisted of 21 samples with I50 ranging from 1.51 to 3 ng/ml, and the third of 17 samples with I50 ranging from 3.01 to 13 ng/ml. The determination coefficient (R² = 0.999) showed that the data obtained by gas chromatography represented a reliable basis. The results obtained by ELISA were also reliable, with an estimated Pearson correlation coefficient of 0.82 between the two methods. This coefficient for the different groups (0.88, 0.79 and 0.49 for groups 1, 2 and 3, respectively) showed greater reliability for the test with dilutions closer to I50.

Avaliaram-semos os efeitos das injeções intravenosas (iv) de amitraz (0,1mg/kg) e xilazina (1mg/kg), em cavalos, sobre a atividade cardíaca, freqüência respiratória, atividade motora intestinal, temperatura retal, sudorese e freqüência de apreensão de alimentos. O amitraz causouuma diminuição significativa da atividade cardíaca, da freqüência respiratória e da movimentação intestinal, mas esses efeitos não foram tão pronunciados quanto os causados pela xilazina. O amitraz causou, também, um relaxamento significativo da musculatura lisa retal, e um aparente aumento da sudorese e da freqüência de cavalos flagrados mastigando feno. A temperatura retal não foi influenciada pelo amitraz. Os resultados indicam que o amitraz, na dose utilizada, não causou efeitos colaterais severos em cavalos.

The effect of the intravenous injection of amitraz (0.1mg/kg) to horses on cardiac activity, respiratory rate, intestinal motor activity, rectal temperature, sweating and masticating was evaluated and compared to the effect of intravenous administration of xylazine (1mg/kg, iv) on heart rate, respiratory rate and intestinal activity. Amitraz caused a significant decrease in heart activity, respiratory rate and intestinal movements, but these effects were not as pronounced as those caused by xylazine. Amitraz also caused a significant relaxation of the rectal smooth muscle, and an apparent increase in sweating and in the frequency of horses found masticating hay. Rectal temperature was not influenced by amitraz. The results indicated that amitraz, at the dose used, did not cause severe side effects in horses.